Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA

ABSTRACT: RNA-seq of human pancreatic cancer.

TISSUE(S): ['pancreas']

SUBMITTER: yunguang Li

PROVIDER: OEX00012195 | NODE | 2021-01-30

REPOSITORIES: NODE

ACCESS DATA

Json Xml

Similar Datasets

RNA sequencing of human pancreatic cancer cell lines

Project description:RNA-seq profiling was conducted on human pancreatic cancer cell lines We measured the transcriptome in 14 human pancreatic cancer cell linees

2016-06-11 | E-GEOD-79669 | biostudies-arrayexpress

RNA-sequencing of human pancreatic adenocarcinoma cancer tissues

Project description:RNA-seq profiling was conducted on clinically-annotated human pancreatic adenocarcinoma cancer tissues We measured the transcriptome in 51 clinically-annotated human pancreatic adenocarcinoma cancer tissues

2016-06-11 | E-GEOD-79668 | biostudies-arrayexpress

Metabolic reprogramming is an initial step in pancreatic carcinogenesis that can be targeted to inhibit acinar-to-ductal metaplasia

Project description:<p>Metabolic reprogramming is a hallmark of cancer and is crucial for cancer progression, making it an attractive therapeutic target. Understanding the role of metabolic reprogramming in cancer initiation could help identify prevention strategies. To address this, we investigated metabolism during acinar-to-ductal metaplasia (ADM), the first step of pancreatic carcinogenesis. Glycolytic markers were elevated in ADM lesions compared to normal tissue from human samples. Comprehensive metabolic assessment in three mouse models with pancreas-specific activation of KRAS, PI3K or MEK1 using Seahorse measurements, NMR metabolome analysis, mass spectrometry, isotope tracing and RNA-seq analysis revealed a switch from oxidative phosphorylation to glycolysis in ADM. Blocking the metabolic switch attenuated ADM formation. Furthermore, mitochondrial metabolism was required for de novo synthesis of serine and glutathione but not for ATP production. MYC mediated the increase in GSH intermediates in ADM, and inhibition of GSH synthesis suppressed ADM development. This study thus identifies metabolic changes and vulnerabilities in the early stages of pancreatic carcinogenesis.</p>

2024-05-31 | MTBLS9772 | MetaboLights

RNA sequencing of human pancreatic cancer cell lines

Project description:RNA-seq profiling was conducted on human pancreatic cancer cell lines

2016-06-11 | GSE79669 | GEO

RNA-sequencing of human pancreatic adenocarcinoma cancer tissues

Project description:RNA-seq profiling was conducted on clinically-annotated human pancreatic adenocarcinoma cancer tissues

2016-06-11 | GSE79668 | GEO

RNA-seq in pancreatic cancer PANC1 cells

Project description:RNA-seq in pancreatic cancer PANC1 cells

| PRJNA542693 | ENA

A Comparative Study of Human Testes and Epididymis through the Proteomics and RNA-seq Methods

Project description:A Comparative Study of Human Testes and Epididymis through the Proteomics and RNA-seq Methods

2021-06-03 | PXD026440 |

Targeting lipid metabolism in pancreatic cancer [RNA-seq]

Project description:Targeting lipid metabolism in pancreatic cancer [RNA-seq]

| PRJNA1074765 | ENA

Engrailed-1 Promotes Pancreatic Cancer Metastasis [RNA-Seq]

Project description:Engrailed-1 Promotes Pancreatic Cancer Metastasis [RNA-Seq]

| PRJNA951668 | ENA

GNPS - pbSMARCD3 is a key epigenetic dependency for pancreatic adenocarcinoma

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a disease characterized by extensive resistance to conventional therapies, making clinical management a significant challenge. As cancer progresses, developmental signals are often aberrantly re-activated, driving the self-renewal of cancer cells and fueling therapy resistance. To understand the epigenetic regulators that may be required to sustain these aggressive cells, we carried out a focused screen and identified SMARCD3 as a new functional dependency in pancreatic cancer. SMARCD3, a subunit of the SWI/SNF nucleosome remodeling complex, was uniquely up-regulated in PDAC stem cells and amplified in human cancer. Using a dual-recombinase model of pancreatic cancer, we showed that stage-specific conditional genetic deletion of Smarcd3 preferentially impaired growth of established tumors, improving survival and synergizing with chemotherapy. Consistent with this, SMARCD3 was required for the in vivo propagation of patient-derived xenografts. Mechanistically, we found that SMARCD3 is incorporated in the BAF complex variant of SWI/SNF. Using comprehensive ChIP-seq analysis to map the SMARCD3-dependent epigenome we showed that Smarcd3 inhibition drives global losses in histone acetylation and BAF binding at active enhancers co-bound by FOXA1. Integrating this with RNA-seq analysis, we found that SMARCD3-BAF regulated a network of genes implicated in diverse programs converging on lipid homeostasis. Specifically, Smarcd3 deletion in vivo inhibited fatty acid metabolism, which is known to be enriched within therapy-resistant cancer cells. These data collectively identify SMARCD3 as a critical dependency in PDAC and link SWI/SNF with the epigenetic control of cell state and metabolism in PDAC.

2022-11-18 | MSV000090744 | GNPS

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data